pharmaphorum4d
Biogen bags rights to epilepsy drug from Stoke in $550m deal
Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from ...
Gene therapy for rare epilepsy shows promise in mice
Dravet syndrome and other developmental epileptic encephalopathies are rare but devastating conditions that cause a host of ...
technologynetworks6d
Epilepsy Gene Therapy Reduces Seizures and Prolongs Lifespan in Mice
Michigan Medicine researchers have developed a SCN1B gene therapy that restores brain function and survival in mice with ...
BioSpace5d
Biogen and Stoke Strike Dravet Syndrome Co-Development Deal
The partnership splits the rights to Stoke’s epilepsy antisense oligonucleotide, with up to $385 million in potential ...
PMLiVE3d
Biogen gains rights to Stoke’s Dravet syndrome candidate in deal worth $550m
Biogen and Stoke Therapeutics have announced a partnership aimed at advancing a disease-modifying treatment for Dravet ...
Pharm Exec3d
Biogen, Stoke Therapeutics Ink Deal to Develop Zorevunersen for Dravet Syndrome
Under terms of the deal, Stoke will spearhead global development of zorevunersen, while Biogen will receive exclusive rights ...
Science Daily10d
Gene therapy for rare epilepsy shows promise in mice
Recent research takes aim at the a variant in gene SCN1B, which causes a severe form of developmental epileptic encephalopathy. Dravet syndrome and other developmental epileptic encephalopathies ...